Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain | Zendy

John F. Peppin | Zendy; Majors | Zendy; Lynn R. Webster | Zendy; Simpson | Zendy; Jeffrey Tobias | Zendy; Vanhove | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain

Author(s) -

John F. Peppin,

Majors,

Lynn R. Webster,

Simpson,

Jeffrey Tobias,

Vanhove

Publication year - 2011

Publication title -

journal of pain research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.888

H-Index - 49

ISSN - 1178-7090

DOI - 10.2147/jpr.s22954

Subject(s) - medicine , tolerability , capsaicin , neuropathic pain , peripheral , anesthesia , pharmacology , adverse effect , receptor

NGX-4010 (QUTENZA(™); NeurogesX Inc, San Mateo, CA), a capsaicin 8% dermal patch, is licensed in the European Union for the treatment of peripheral neuropathic pain (PNP) in nondiabetic adults and in the United States for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN). While NGX-4010 treatment is associated with a low risk of systemic adverse events, patch application-related pain is common and may be managed with local cooling and/or oral analgesics. This article characterizes the tolerability of NGX-4010 and will help to guide any pain management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research